ATE400554T1 - 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten - Google Patents
2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonistenInfo
- Publication number
- ATE400554T1 ATE400554T1 AT99908933T AT99908933T ATE400554T1 AT E400554 T1 ATE400554 T1 AT E400554T1 AT 99908933 T AT99908933 T AT 99908933T AT 99908933 T AT99908933 T AT 99908933T AT E400554 T1 ATE400554 T1 AT E400554T1
- Authority
- AT
- Austria
- Prior art keywords
- muscariine
- arylethyl
- ylmethyl
- piperidine
- receptor antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7611398P | 1998-02-27 | 1998-02-27 | |
| US10909798P | 1998-11-19 | 1998-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE400554T1 true ATE400554T1 (de) | 2008-07-15 |
Family
ID=26757679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99908933T ATE400554T1 (de) | 1998-02-27 | 1999-02-19 | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6319920B1 (de) |
| EP (1) | EP1058680B1 (de) |
| JP (1) | JP3523198B2 (de) |
| KR (1) | KR100384906B1 (de) |
| CN (1) | CN1143848C (de) |
| AR (1) | AR015523A1 (de) |
| AT (1) | ATE400554T1 (de) |
| AU (1) | AU753255B2 (de) |
| BR (1) | BR9909253A (de) |
| CA (1) | CA2321198C (de) |
| CO (1) | CO4990939A1 (de) |
| DE (1) | DE69939053D1 (de) |
| ES (1) | ES2310032T3 (de) |
| HK (1) | HK1036623A1 (de) |
| HR (1) | HRP20000544A2 (de) |
| HU (1) | HUP0100760A3 (de) |
| IL (1) | IL137936A0 (de) |
| MA (1) | MA26610A1 (de) |
| MY (1) | MY133445A (de) |
| NO (1) | NO317106B1 (de) |
| NZ (1) | NZ506317A (de) |
| PE (1) | PE20000325A1 (de) |
| PL (1) | PL194037B1 (de) |
| RU (1) | RU2220138C2 (de) |
| TR (1) | TR200002481T2 (de) |
| WO (1) | WO1999043657A1 (de) |
| YU (1) | YU53100A (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1012150A4 (de) * | 1997-05-19 | 2002-05-29 | Sugen Inc | Heteroarylcarboxamid-verbindungen die gegen durch protein-tyrosin-kinase verursachte krankheiten wirksam sind |
| RU2243222C2 (ru) | 2000-05-25 | 2004-12-27 | Ф.Хоффманн-Ля Рош Аг | Замещенные 1-аминоалкиллактамы, фармацевтическая композиция на их основе и способ их получения |
| DE60114413T2 (de) | 2000-05-25 | 2006-07-27 | F. Hoffmann-La Roche Ag | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten |
| WO2003048125A1 (en) | 2001-12-03 | 2003-06-12 | F. Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
| MXPA04005076A (es) | 2001-12-03 | 2004-08-19 | Hoffmann La Roche | Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico. |
| BR0311414A (pt) * | 2002-06-07 | 2005-03-15 | Yamanouchi Pharma Co Ltd | Agente terapêutico para uma bexiga hiperativa |
| US7399779B2 (en) | 2002-07-08 | 2008-07-15 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists |
| CN100364990C (zh) * | 2002-10-30 | 2008-01-30 | 施万制药 | 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物 |
| TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
| EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
| AU2003301184A1 (en) * | 2002-12-20 | 2004-07-22 | Dynogen Pharmaceuticals Inc | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS |
| CA2519694A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| EP1618091A1 (de) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituierte azabicyclohexanderivate als antagonisten von muscarinrezeptoren |
| BRPI0409302A (pt) | 2003-04-11 | 2006-04-11 | Ranbaxy Lab Ltd | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos |
| WO2005007645A1 (en) * | 2003-07-11 | 2005-01-27 | Theravance, Inc. | Substituted 4-amino-1-benzylpiperidine compounds |
| US7214439B2 (en) * | 2003-12-19 | 2007-05-08 | Millennium Cell, Inc. | Triborohydride salts as hydrogen storage materials and preparation thereof |
| CA2682032A1 (en) * | 2007-04-24 | 2008-11-06 | Theravance, Inc. | Quaternary ammonium compounds useful as muscarinic receptor antagonists |
| DE102007020492A1 (de) * | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
| EP3170807B1 (de) * | 2015-11-23 | 2019-12-11 | Frau Pharma S.r.l. | Neues verfahren zur synthese von fenfluramin |
| SI25272A (sl) | 2016-09-23 | 2018-03-30 | Univerza V Ljubljani | Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni |
| CN112824378A (zh) * | 2019-11-20 | 2021-05-21 | 珠海润都制药股份有限公司 | 一种盐酸坦索罗辛的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0361791B1 (de) | 1988-09-26 | 1995-11-08 | Smithkline Beecham Farmaceutici S.p.A. | Azacyclische Verbindungen, verwendbar als Arzneimittel |
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| FR2681320B1 (fr) | 1991-09-12 | 1994-01-14 | Synthelabo | Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique. |
| FR2681325B1 (fr) | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique. |
| AU7129596A (en) | 1995-09-15 | 1997-04-01 | Neurosearch A/S | Piperidine compounds as calcium channel blockers |
| US6130232A (en) * | 1995-10-13 | 2000-10-10 | Banyu Pharmaceutical Coaltd | Substituted piperidine derivatives as muscarinic M3 receptor antagonists |
-
1999
- 1999-02-01 US US09/241,816 patent/US6319920B1/en not_active Expired - Fee Related
- 1999-02-19 TR TR2000/02481T patent/TR200002481T2/xx unknown
- 1999-02-19 HU HU0100760A patent/HUP0100760A3/hu unknown
- 1999-02-19 AT AT99908933T patent/ATE400554T1/de not_active IP Right Cessation
- 1999-02-19 CN CNB998045322A patent/CN1143848C/zh not_active Expired - Fee Related
- 1999-02-19 NZ NZ506317A patent/NZ506317A/en unknown
- 1999-02-19 RU RU2000124676/04A patent/RU2220138C2/ru not_active IP Right Cessation
- 1999-02-19 BR BR9909253-0A patent/BR9909253A/pt not_active Application Discontinuation
- 1999-02-19 YU YU53100A patent/YU53100A/sh unknown
- 1999-02-19 CA CA002321198A patent/CA2321198C/en not_active Expired - Fee Related
- 1999-02-19 AU AU28353/99A patent/AU753255B2/en not_active Ceased
- 1999-02-19 WO PCT/EP1999/001102 patent/WO1999043657A1/en active IP Right Grant
- 1999-02-19 IL IL13793699A patent/IL137936A0/xx unknown
- 1999-02-19 JP JP2000533415A patent/JP3523198B2/ja not_active Expired - Fee Related
- 1999-02-19 ES ES99908933T patent/ES2310032T3/es not_active Expired - Lifetime
- 1999-02-19 EP EP99908933A patent/EP1058680B1/de not_active Expired - Lifetime
- 1999-02-19 PL PL99342692A patent/PL194037B1/pl unknown
- 1999-02-19 KR KR10-2000-7009431A patent/KR100384906B1/ko not_active IP Right Cessation
- 1999-02-19 DE DE69939053T patent/DE69939053D1/de not_active Expired - Lifetime
- 1999-02-23 PE PE1999000155A patent/PE20000325A1/es not_active Application Discontinuation
- 1999-02-24 CO CO99011501A patent/CO4990939A1/es unknown
- 1999-02-24 AR ARP990100772A patent/AR015523A1/es not_active Application Discontinuation
- 1999-02-25 MA MA25473A patent/MA26610A1/fr unknown
- 1999-02-25 MY MYPI99000700A patent/MY133445A/en unknown
-
2000
- 2000-08-18 HR HR20000544A patent/HRP20000544A2/hr not_active Application Discontinuation
- 2000-08-25 NO NO20004261A patent/NO317106B1/no unknown
-
2001
- 2001-10-18 HK HK01107289A patent/HK1036623A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69939053D1 (de) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten | |
| DE60023167T2 (de) | Pyrazol-derivate als cannabinoidrezeptor-antagonisten | |
| NO20012411D0 (no) | Pyrrolidin-derivater-CCR-3-reseptorantagonister | |
| ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
| ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
| ATE280157T1 (de) | 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii | |
| ATE299866T1 (de) | Piperidinderivate verwendbar als ccr5 antagonisten | |
| ATE263151T1 (de) | Indolderivate verwendbar als endothelinrezeptorantagonisten | |
| ATE272632T1 (de) | Muskarin-rezeptor antagonisten | |
| ATE416173T1 (de) | 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4- benzylpiperidine als nmda-rezeptor-antagonisten | |
| NO20004503D0 (no) | Vitronectin-reseptor-antagonister | |
| ATE286022T1 (de) | Naphthalin-carboxamide als tachykinin rezeptorantagonisten | |
| NO20016053L (no) | IL-8 reseptor-antagonister | |
| ATE244716T1 (de) | Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten | |
| NO20016052D0 (no) | IL-8-reseptor-antagonister | |
| ATE196766T1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten | |
| DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
| ATE277043T1 (de) | Vitronectin rezeptor antagonist | |
| DK1180028T3 (da) | IL-8-receptorantagonister | |
| ATE338043T1 (de) | 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten | |
| ATE228514T1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten | |
| NO20015774L (no) | IL-8 reseptorantagonister | |
| ATE206421T1 (de) | Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten | |
| NO20010620D0 (no) | Vitronektinreseptor-antagonister | |
| NO20016102D0 (no) | IL-8 reseptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |